- Home
- DRUG vs ZH Comparison
DRUG vs ZH Comparison
Compare DRUG & ZH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRUG
- ZH
- Stock Information
- Founded
- DRUG 2019
- ZH 2011
- Country
- DRUG United States
- ZH China
- Employees
- DRUG N/A
- ZH N/A
- Industry
- DRUG Pharmaceuticals and Biotechnology
- ZH Business Services
- Sector
- DRUG Health Care
- ZH Consumer Discretionary
- Exchange
- DRUG Nasdaq
- ZH Nasdaq
- Market Cap
- DRUG 484.7M
- ZH 397.3M
- IPO Year
- DRUG N/A
- ZH 2021
- Fundamental
- Price
- DRUG $69.38
- ZH $4.32
- Analyst Decision
- DRUG Strong Buy
- ZH Strong Buy
- Analyst Count
- DRUG 9
- ZH 1
- Target Price
- DRUG $81.67
- ZH $4.70
- AVG Volume (30 Days)
- DRUG 108.7K
- ZH 240.4K
- Earning Date
- DRUG 08-11-2025
- ZH 11-25-2025
- Dividend Yield
- DRUG N/A
- ZH N/A
- EPS Growth
- DRUG N/A
- ZH N/A
- EPS
- DRUG N/A
- ZH 0.22
- Revenue
- DRUG N/A
- ZH $439,821,184.00
- Revenue This Year
- DRUG N/A
- ZH N/A
- Revenue Next Year
- DRUG N/A
- ZH $6.47
- P/E Ratio
- DRUG N/A
- ZH $19.64
- Revenue Growth
- DRUG N/A
- ZH N/A
- 52 Week Low
- DRUG $23.18
- ZH $3.13
- 52 Week High
- DRUG $70.23
- ZH $6.32
- Technical
- Relative Strength Index (RSI)
- DRUG 68.34
- ZH 34.98
- Support Level
- DRUG $62.21
- ZH $4.21
- Resistance Level
- DRUG $70.23
- ZH $5.04
- Average True Range (ATR)
- DRUG 6.00
- ZH 0.19
- MACD
- DRUG 0.52
- ZH -0.07
- Stochastic Oscillator
- DRUG 96.01
- ZH 10.58
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
About ZH Zhihu Inc. (every two of each representing one ordinary share)
Zhihu Inc is predominantly engaged in the operation of one online content community and monetizes through paid membership services, advertising services, content-commerce solutions services, and vocational training in China. It generates revenues from Advertising services, Paid membership services, Content-commerce solutions, and Others. It derives all its revenues within China.